Global MSD Drugs Market Size By Type (OTC, Rx Drugs), By Application (Hospital, Retail Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global MSD (Merck & Co., Inc.) Drugs Market was valued at USD 54.7 billion in 2023 and is projected to reach USD 97.3 billion by 2031, expanding at a CAGR of 7.4% during the forecast period (2023–2031). The growth is primarily driven by the increasing demand for oncology treatments, expanding R&D initiatives in vaccines and infectious diseases, and strong product pipelines including blockbuster drugs like Keytruda, Gardasil, and Januvia. MSD’s focus on immunotherapy and chronic disease treatment contributes significantly to market momentum, making it a key player in the global pharmaceutical landscape.

Drivers:

1. Surge in Oncology Drug Demand:

MSD’s immuno-oncology portfolio, led by Keytruda, continues to dominate the cancer therapeutics market. The increasing incidence of cancer globally and the success of checkpoint inhibitors are fueling demand.

2. Expanding Vaccination Programs:

MSD’s vaccines, particularly Gardasil for HPV, are witnessing increased uptake due to rising awareness and government immunization programs.

3. Innovation in Chronic Disease Management:

MSD’s drugs for diabetes and cardiovascular diseases, including Januvia and Steglatro, remain vital as global diabetes prevalence surges.

Restraints:

1. Patent Expiry and Generic Competition:

Several MSD drugs are nearing patent expiration, making them vulnerable to generic drug entry, which can significantly impact revenue.

2. Regulatory and Pricing Pressure:

Tightening regulatory requirements and increasing global scrutiny on drug pricing pose potential risks to revenue growth, particularly in price-sensitive regions.

Opportunity:

1. Expansion in Emerging Markets:

Rapid urbanization, rising healthcare expenditure, and improving healthcare access in Asia-Pacific, Latin America, and the Middle East present lucrative growth opportunities for MSD.

2. Accelerated R&D in mRNA and AI-Based Drug Discovery:

MSD's investment in emerging technologies such as mRNA platforms and AI-driven drug discovery can pave the way for next-generation therapeutics.

Market by Drug Type Insights:

The Oncology Drugs segment accounted for the largest revenue share in 2023, led by the success of Keytruda. The drug’s expanding label across multiple cancer types, including lung, melanoma, and renal cancer, is expected to sustain this dominance. Vaccines are the fastest-growing segment, driven by increasing global uptake of Gardasil and growing awareness of preventable diseases.

Market by End-use Insights:

Hospitals remained the leading end-use segment in 2023, driven by higher inpatient drug administration, particularly for oncology and infectious diseases. Retail Pharmacies are anticipated to witness substantial growth due to increasing self-medication trends and chronic disease prescriptions being filled in outpatient settings.

Market by Regional Insights:

North America led the market in 2023, with the U.S. being MSD’s largest market due to advanced healthcare infrastructure, favorable reimbursement scenarios, and early adoption of novel drugs. Asia-Pacific is projected to record the highest CAGR during the forecast period due to rising healthcare investments, growing middle-class population, and increasing incidence of chronic diseases.

Competitive Scenario:

MSD remains a dominant force in the pharmaceutical market through strategic acquisitions, R&D investment, and partnerships. Notable developments include:

2023: MSD expanded Keytruda’s approval for triple-negative breast cancer in Europe.

2024: The company acquired Prometheus Biosciences to enhance its immunology pipeline.

2025: MSD partnered with Moderna to co-develop mRNA-based cancer vaccines.

Scope of Work – Global MSD Drugs Market

Key Market Developments:

2023: MSD’s Keytruda received FDA priority review for early-stage non-small cell lung cancer.

2024: The company launched a new HPV vaccine production facility in India.

2025: Collaborated with AI startups for drug repurposing in rare diseases.

FAQs:

1) What is the current market size of the Global MSD Drugs Market?

The market was valued at USD 54.7 billion in 2023.

2) What is the major growth driver of the Global MSD Drugs Market?

The growing demand for oncology and vaccine therapies is the key growth driver.

3) Which is the largest region during the forecast period in the Global MSD Drugs Market?

North America is the largest region due to advanced healthcare infrastructure and high drug adoption.

4) Which segment accounted for the largest market share in Global MSD Drugs Market?

The Oncology Drugs segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global MSD Drugs Market?

Key players include Merck & Co., Inc. (MSD), Pfizer Inc., Roche Holding AG, Bristol Myers Squibb, and AstraZeneca.